Nervgen Pharma Corp Stock Current Valuation
| NGEN Stock | CAD 3.09 0.11 3.69% |
Valuation analysis of NervGen Pharma Corp helps investors to measure NervGen Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -7.93 in 2025. Enterprise Value Multiple is likely to drop to -7.93 in 2025. Fundamental drivers impacting NervGen Pharma's valuation include:
Overvalued
Today
Please note that NervGen Pharma's price fluctuation is very risky at this time. Calculation of the real value of NervGen Pharma Corp is based on 3 months time horizon. Increasing NervGen Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NervGen stock is determined by what a typical buyer is willing to pay for full or partial control of NervGen Pharma Corp. Since NervGen Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NervGen Stock. However, NervGen Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.09 | Real 2.9 | Hype 3.09 | Naive 3.0 |
The intrinsic value of NervGen Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NervGen Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NervGen Pharma Corp helps investors to forecast how NervGen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NervGen Pharma more accurately as focusing exclusively on NervGen Pharma's fundamentals will not take into account other important factors: NervGen Pharma Corp Company Current Valuation Analysis
NervGen Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current NervGen Pharma Current Valuation | 188.64 M |
Most of NervGen Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NervGen Pharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NervGen Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for NervGen Pharma is extremely important. It helps to project a fair market value of NervGen Stock properly, considering its historical fundamentals such as Current Valuation. Since NervGen Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NervGen Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NervGen Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, NervGen Pharma Corp has a Current Valuation of 188.64 M. This is 98.69% lower than that of the Biotechnology sector and 95.94% lower than that of the Health Care industry. The current valuation for all Canada stocks is 98.87% higher than that of the company.
NervGen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NervGen Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NervGen Pharma could also be used in its relative valuation, which is a method of valuing NervGen Pharma by comparing valuation metrics of similar companies.NervGen Pharma is currently under evaluation in current valuation category among its peers.
NervGen Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of NervGen Pharma from analyzing NervGen Pharma's financial statements. These drivers represent accounts that assess NervGen Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NervGen Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 44.9M | 46.7M | 66.0M | 90.3M | 81.3M | 47.2M |
NervGen Fundamentals
| Return On Equity | -2.3 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 188.64 M | ||||
| Shares Outstanding | 70.31 M | ||||
| Shares Owned By Insiders | 22.91 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Number Of Shares Shorted | 199.54 K | ||||
| Price To Book | 22.83 X | ||||
| EBITDA | (19.24 M) | ||||
| Net Income | (22.38 M) | ||||
| Cash And Equivalents | 8.27 M | ||||
| Cash Per Share | 0.30 X | ||||
| Total Debt | 15.25 M | ||||
| Current Ratio | 25.72 X | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (11.3 M) | ||||
| Short Ratio | 4.77 X | ||||
| Earnings Per Share | (0.38) X | ||||
| Target Price | 4.5 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 209.52 M | ||||
| Total Asset | 13.24 M | ||||
| Retained Earnings | (78.15 M) | ||||
| Working Capital | (2.62 M) | ||||
| Net Asset | 13.24 M |
About NervGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NervGen Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NervGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NervGen Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.